Castuner

PharmOncology

Ming-Hei Tai

A podcast about pharmacy and oncology

Podcast website

Listen in your app

Episodes

28 episodes

  1. Why new first line DLBCL trials have two extra cycles of rituximab for R-CHOP 9:49
  2. Savolitinib, osimertinib, and how we should be targeting EGFR mutated lung cancer after relapse 10:14
  3. A Review of DeLLphi-305 12:49
  4. Is daraxonrasib actually pan-RAS? 11:57
  5. How hepatotoxic is tucatinib? 11:16
  6. How do ADCs actually work? 9:48
  7. Clinical Trial Representativeness in Oncology 9:00
  8. Why MMAE beat MMAF 11:01
  9. Sequencing agents in HER2 mutant lung cancer 16:30
  10. Does levetiracetam makes sense for ICANS? 9:30
  11. Is zanidatamab better than trastuzumab in HER2 IHC 2+? 12:11
  12. ESR1 mutations, elacestrant, imlunestrant, and vepdegestrant 10:48
  13. Explaining CELMoDs in 10 minutes 9:22
  14. Does chemo work in extensive stage small cell lung cancer? 9:24
  15. Why current HER2 testing is flawed 11:48
  16. Chemotherapy (and especially platinum) Resistance 12:12
  17. VIKTORIA-1: Appropriate control arm? 11:40
  18. What's the difference between the DLBCL second-line regimens? 15:41
  19. Why don't we have a pan-tumor drug that targets BRCA mutations? 7:38
  20. DESTINY-Breast11 and Surrogate Endpoints 6:36
  21. The Fc region of antibodies 9:22
  22. CIRCULATE and ctDNA positivity rates 8:33
  23. The dangers of cross-trial comparisons 7:42
  24. Thoughts on RASolute 302 (for 20 minutes) 20:46
  25. ADC Sequencing and the "Sandwich" method 9:06
  26. Is HRR really a biomarker in prostate cancer? 7:39
  27. Interpreting prospective ctDNA trials 14:43
  28. Why we should look at continuing CD38 antibodies after progression 9:32